Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 7/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121805 | 1.00 | ALDH1A1 (0.45) | ALDH1A1EPHX1ATMTSHRHPGD | |
| SCHEMBL121806 | 1.00 | ALDH1A1 (0.45) | ALDH1A1EPHX1ATMTSHRHPGD | |
| SCHEMBL121407 | 0.93 | EPHX1 (0.53) | ALDH1A1EPHX1TSHRACHEHCAR2 | |
| SCHEMBL112043 | 0.93 | EPHX1 (0.53) | ALDH1A1EPHX1TSHRACHEHCAR2 | |
| SCHEMBL113441 | 0.93 | EPHX1 (0.53) | ALDH1A1EPHX1TSHRACHEHCAR2 | |
| SCHEMBL121408 | 0.93 | EPHX1 (0.53) | ALDH1A1EPHX1TSHRACHEHCAR2 | |
| SCHEMBL111056 | 0.93 | EPHX1 (0.53) | ALDH1A1EPHX1TSHRACHEHCAR2 | |
| SCHEMBL111373 | 0.93 | EPHX1 (0.53) | ALDH1A1EPHX1TSHRACHEHCAR2 | |
| SCHEMBL109499 | 0.93 | EPHX1 (0.53) | ALDH1A1EPHX1TSHRACHEHCAR2 | |
| SCHEMBL113196 | 0.89 | KDM4E (0.35) | ALDH1A1EPHX1TSHRACHEHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| CN-105820138-A | ABT-263 crystalline forms and solvates for use in treating BCL-2 protein related diseases | ABBVIE 公司 | 2016-08-03 | — | — | CN | disclosed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8362013-B2 | Salt of ABT-263 and solid-state forms thereof | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362014-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102802609-A | Stable Nanoparticle Drug Suspensions | ABBOTT LAB | 2012-11-28 | — | — | CN | disclosed |
| EP-2515883-A1 | ABT-263 CAPSULE | Abbott Laboratories (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110294811-A1 | ABT-263 CRYSTALLINE FORMS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011079127-A1 | ABT-263 CAPSULE | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110159085-A1 | ABT-263 CAPSULE | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110071151-A1 | ABT-263 CRYSTALLINE FORMS | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBVIE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES | 2010-11-25 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | BCL2L10, TMBIM6, BCOR | ALDH1A1 2745/4885EPHX1 4611/4885ATM 3548/4885 |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCL2L2 | ALDH1A1 3413/4885EPHX1 4586/4885ATM 2253/4885 |
| US-20110071151-A1 | ABT-263 CRYSTALLINE FORMS | BCL3, BCL2, BCL2L13 | ALDH1A1 4262/4885EPHX1 4857/4885ATM 466/4885 |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | BCL3, BCL2, BCL2L13 | ALDH1A1 4223/4885EPHX1 4845/4885ATM 538/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | ALDH1A1 3985/4885EPHX1 4584/4885ATM 2737/4885 |
| US-20110294811-A1 | ABT-263 CRYSTALLINE FORMS | BCL3, BCL2, BCL2L13 | ALDH1A1 4262/4885EPHX1 4857/4885ATM 466/4885 |
| US-20110159085-A1 | ABT-263 CAPSULE | BCL2, BCL2L13, BCL2L10 | ALDH1A1 3188/4885EPHX1 4680/4885ATM 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.